基于诺福克生活质量在糖尿病周围神经病变问卷的新型分项死亡率风险评分对罗马尼亚糖尿病患者的预测价值。

Predictive value of a novel sub-item mortality risk score derived from the Norfolk Quality of Life in Diabetic Neuropathy questionnaire in Romanian participants with diabetes mellitus.

机构信息

Department of Medical Informatics and Biostatistics, Iuliu Haţieganu University of Medicine and Pharmacy, 6 Pasteur street, 400349 Cluj-Napoca, Romania.

Cluj-Napoca County Emergency Hospital, Centre of Diabetes, Nutrition and Metabolic Diseases, 2 Clinicilor street, 400006 Cluj-Napoca, Romania.

出版信息

Prim Care Diabetes. 2022 Oct;16(5):684-691. doi: 10.1016/j.pcd.2022.07.005. Epub 2022 Jul 30.

DOI:10.1016/j.pcd.2022.07.005

PMID:35915012

Abstract

AIMS

To evaluate whether the Norfolk Quality of Life in Diabetic Neuropathy (QOL-DN) questionnaire and the novel Norfolk Mortality Risk Score (NMRS), comprising Norfolk QOL-DN items, can identify 4-year mortality risk in individuals with diabetes.

METHODS

Of 21,756 adults completing Norfolk QOL-DN in 2012, two groups of surviving and deceased patients were identified in 2016: Group 1, from a county capital and Group 2, from six small cities. NMRS was calculated in Group 1 using the 2012 scores of Norfolk QOL-DN items that discriminate between deceased and surviving participants (p < 0.05) and was subsequently applied to Group 2.

RESULTS

763 participants were included (Group 1: 481 [450 surviving, 31 deceased]; Group 2: 282 [218 surviving, 64 deceased]). Total Norfolk QOL-DN score was significantly higher (worse) in deceased participants than in survivors in both groups (p ≤ 0.008). Optimal cut-off for the 25-item NMRS was 11.5 in Group 1. Individuals in Groups 1 and 2 with NMRS≥ 11.5 in 2012 had a 4-year mortality risk ratio of 4.24 (95 % confidence interval [CI]: 1.65-10.84) and 2.33 (95 % CI: 1.33-4.07), respectively, corresponding to 8 and 16 additional deaths/100 persons/4 years (p = 0.001).

CONCLUSION

Norfolk QOL-DN and NMRS can identify individuals with diabetes at risk of 4-year mortality.

摘要

目的

评估诺福克糖尿病神经病变生活质量问卷（QOL-DN）和包含诺福克 QOL-DN 项目的新型诺福克死亡率风险评分（NMRS）是否可识别糖尿病患者的 4 年死亡风险。

方法

在 2012 年完成诺福克 QOL-DN 的 21756 名成年人中，2016 年确定了两组存活和死亡患者：组 1，来自县城；组 2，来自六个小城市。在组 1 中使用能区分死亡和存活参与者的诺福克 QOL-DN 项目的 2012 评分计算 NMRS（p < 0.05），随后应用于组 2。

结果

共纳入 763 名参与者（组 1：481 名[450 名存活，31 名死亡]；组 2：282 名[218 名存活，64 名死亡]）。两组中，死亡参与者的总诺福克 QOL-DN 评分均显著高于（更差）存活参与者（p <= 0.008）。组 1 中 25 项 NMRS 的最佳截断值为 11.5。2012 年 NMRS >= 11.5 的组 1 和组 2 个体的 4 年死亡率风险比分别为 4.24（95%置信区间[CI]：1.65-10.84）和 2.33（95% CI：1.33-4.07），分别对应每 100 人/4 年 8 例和 16 例额外死亡（p = 0.001）。